Yatharth Hospital & Trauma Care Services · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
112 days DSO is significantly elevated, though management targets 90-95 days improvement. Cash conversion remains strong at 98%, but working capital tied up in receivables could limit flexibility during expansion.
Delhi new hospital and Faridabad Sector 20 incurred Q4 losses of Rs 21 crore and Rs 9 crore respectively, creating ~2% EBITDA drag. Break-even not expected until H2 FY27, temporarily constraining margin expansion.
Government schemes (CGHS, ECHS, ESI, Ayushman) constitute ~35% of revenue. While margins are similar across CGHS/ECHS/ESI, Ayushman has significantly lower margins. Management targets reducing government mix to 25%, but execution risk exists.
NPPA price controls on certain chemotherapy drugs affecting ~20-30% of oncology revenue. With oncology being only 10% of group revenue, impact is marginal but warrants monitoring as this segment grows.
